Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacology and Therapeutics

• Publication date

  2017-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2017.05.013PMID 28564583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

  2017cited by this paper
• Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice

  2017cited by this paper
• HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

  2017cited by this paper
• FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling

  2016cited by this paper
• Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors.

  2016cited by this paper
• Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use

  2016cited by this paper
• Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling.

  2016cited by this paper
• Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment

  2016cited by this paper
• Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors

  2016cited by this paper
• Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.

  2016cited by this paper
• Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

  2016cited by this paper
• Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy

  2016cited by this paper
• A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

  2016cited by this paper
• Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

  2016cited by this paper
• Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients

  2016cited by this paper
• NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of esophageal cancer regulates the survival and migration of tumor-associated macrophages and cancer cells.

  2016cited by this paper
• Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.

  2016cited by this paper
• Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230

  2016cited by this paper
• A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers

  2015cited by this paper
• Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

  2015cited by this paper
• FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7

  2015cited by this paper
• Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance.

  2015cited by this paper
• Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination

  2015cited by this paper
• Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer

  2015cited by this paper
• The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis

  2015cited by this paper
• Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

  2015cited by this paper
• Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction.

  2015cited by this paper
• Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

  2015cited by this paper
• Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use

  2015cited by this paper
• Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation

  2015cited by this paper
• A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

  2015cited by this paper
• FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.

  2015cited by this paper
• Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention.

  2015cited by this paper
• The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma

  2015cited by this paper
• The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

  2015cited by this paper
• Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.

  2015cited by this paper
• The Fibroblast Growth Factor signaling pathway

  2015cited by this paper
• LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.

  2015cited by this paper
• Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy

  2015cited by this paper
• Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease

  2015cited by this paper
• Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

  2014cited by this paper
• Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.

  2014cited by this paper
• Cell-intrinsic lysosomal lipolysis is essential for macrophage alternative activation

  2014cited by this paper
• A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth

  2014cited by this paper
• The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

  2014cited by this paper
• FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

  2014cited by this paper
• Crosstalk with Cancer-Associated Fibroblasts Increases the Growth and Radiation Survival of Cervical Cancer Cells

  2014cited by this paper
• Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion

  2014cited by this paper
• Protein-protein docking: from interaction to interactome.

  2014cited by this paper
• Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.

  2013cited by this paper
• Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.

  2013cited by this paper
• A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

  2013cited by this paper
• Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer.

  2013cited by this paper
• Microenvironmental regulation of tumor progression and metastasis

  2013cited by this paper
• FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

  2013cited by this paper
• Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

  2013cited by this paper
• Small molecule inhibition of fibroblast growth factor receptors in cancer.

  2013cited by this paper
• Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment

  2013cited by this paper
• Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

  2013cited by this paper
• Pathophysiology of heparan sulphate: many diseases, few drugs

  2013cited by this paper
• Modulation of Insulin-Like Growth Factor-1 Receptor and its Signaling Network for the Treatment of Cancer: Current Status and Future Perspectives

  2013cited by this paper
• Identification of targetable FGFR gene fusions in diverse cancers.

  2013cited by this paper
• ERK-Mediated Phosphorylation of Fibroblast Growth Factor Receptor 1 on Ser777 Inhibits Signaling

  2013cited by this paper
• Exploring mechanisms of FGF signalling through the lens of structural biology

  2013cited by this paper
• Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

  2013cited by this paper
• Long pentraxin‐3 as an epithelial–stromal fibroblast growth factor‐targeting inhibitor in prostate cancer

  2013cited by this paper
• Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing

  2013cited by this paper
• Protein-protein interaction networks: the puzzling riches.

  2013cited by this paper
• FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.

  2013cited by this paper
• Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.

  2013cited by this paper
• Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

  2013cited by this paper
• Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

  2013cited by this paper
• Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer

  2013cited by this paper
• Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells

  2013cited by this paper
• Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature

  2012cited by this paper
• FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

  2012cited by this paper
• Myeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective

  2012cited by this paper
• AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

  2012cited by this paper
• Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer

  2012cited by this paper
• Large-scale mapping of human protein interactome using structural complexes

  2012cited by this paper
• Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240

  2012cited by this paper
• Semi-synthetic heparinoids.

  2012cited by this paper
• Heparin-like Polysaccharides Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis

  2012cited by this paper
• Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

  2012cited by this paper
• Brivanib: a review of development.

  2012cited by this paper
• A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

  2012cited by this paper
• Oncogenic FGFR3 gene fusions in bladder cancer

  2012cited by this paper
• Mechanisms of FGFR3 actions in endocrine resistant breast cancer

  2012cited by this paper
• Cancer-related inflammation: common themes and therapeutic opportunities.

  2012cited by this paper
• The structural biology of the FGF19 subfamily.

  2012cited by this paper
• Immunology in the clinic review series; focus on cancer: tumour‐associated macrophages: undisputed stars of the inflammatory tumour microenvironment

  2012cited by this paper
• Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

  2012cited by this paper
• Anti‐FGF‐23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice

  2011cited by this paper
• Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer

  2011cited by this paper
• FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo

  2011cited by this paper
• E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

  2011cited by this paper
• E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.

  2011cited by this paper
• Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

  2011cited by this paper
• Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells

  2011cited by this paper
• A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

  2011cited by this paper

• Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes

  2026cites this paper
• Isolation, structural characterization of natural chondroitin sulfate oligosaccharides and their binding study with anti-angiogenic factors.

  2025cites this paper
• Transcriptome integration analysis revealed that miR-103-3p regulates goat myoblast proliferation by targeting FGF18

  2025cites this paper
• Autocrine Fibroblast Growth Factor Receptor 1 Signaling Activates Lactate Dehydrogenase A-Aerobic Glycolysis for Advanced Human Prostate Tumor Growth

  2025cites this paper
• Cancer associated fibroblasts in cancer development and therapy

  2025cites this paper
• Targeting tumor angiogenesis and metabolism: a new perspective in pediatric thoracic tumor therapy

  2025cites this paper
• Bioactive hemostatic materials: a new strategy for promoting wound healing and tissue regeneration

  2025cites this paper
• Integrative Multi‐Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN‐2, a Covalent FGFR Inhibitor

  2025cites this paper
• Novel FGFR Inhibitor Combined with Radiotherapy Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death Improving Anti-Tumor Activity.

  2025cites this paper
• Current insights and barriers in FGFR-mediated signaling in lung cancer.

  2025cites this paper
• Autophagy regulation in ovarian cancer chemoresistance: Molecular mechanisms and emerging frontiers.

  2025cites this paper
• Inhalable Chemotactic Liposome for Targeted Modulation of Pulmonary Pre‐Metastatic Niche

  2025cites this paper
• Cancer stem-like cells in uveal melanoma: Novel insights and therapeutic implications.

  2024cites this paper
• FGF2 promotes the proliferation of injured granulosa cells in premature ovarian failure via Hippo-YAP signaling pathway.

  2024cites this paper
• Comparative Analysis of Olive-Derived Phenolic Compounds’ Pro-Melanogenesis Effects on B16F10 Cells and Epidermal Human Melanocytes

  2024cites this paper
• Fibroblast Growth Factor 6.

  2024cites this paper
• Microsatellite instability: A potential game-changer in colorectal cancer diagnosis and treatment

  2024cites this paper
• Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells

  2024cites this paper
• FLRT3 and TGF‐β/SMAD4 signalling: Impacts on apoptosis, autophagy and ion channels in supraventricular tachycardia

  2024cites this paper
• A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update

  2024cites this paper
• Fabrication of a Coculture Organoid Model in the Biomimetic Matrix of Alginate to Investigate Breast Cancer Progression in a TAMs-Leading Immune Microenvironment.

  2024cites this paper
• Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool

  2024cites this paper
• THBS1 promotes angiogenesis and accelerates ESCC malignant progression by the HIF‐1/VEGF signaling pathway

  2024cites this paper
• Assessing angiogenesis factors as prognostic biomarkers in breast cancer patients and their association with clinicopathological factors

  2024cites this paper
• FGF20 Secreted From Dermal Papilla Cells Regulate the Proliferation and Differentiation of Hair Follicle Stem Cells in Fine‐Wool Sheep

  2024cites this paper
• Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

  2024cites this paper
• Comprehensive in silico analysis of prognostic and immune infiltrates for FGFs in human ovarian cancer

  2024cites this paper
• Overcoming drug resistance of cancer cells by targeting the FGF1/FGFR1 axis with honokiol or FGF ligand trap

  2024cites this paper
• Dendrimer-mediated targeting of angiogenic biomarkers: therapeutic intervention against cancer

  2024cites this paper
• The effect of genetics and biochemistry on the pathogenesis of cholangiocarcinoma

  2024cites this paper
• Discovery of novel FGF trap small molecules endowed with anti-myeloma activity.

  2024cites this paper
• Integrating single‐cell and spatial analysis reveals MUC1‐mediated cellular crosstalk in mucinous colorectal adenocarcinoma

  2024cites this paper
• Panoramic RNA expression of fibroblast growth factors in human glioblastoma tissues and the impact on the survival of patients

  2024cites this paper
• PKM2 functions as a histidine kinase to phosphorylate PGAM1 and increase glycolysis shunts in cancer

  2024cites this paper
• Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.

  2024cites this paper
• FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer

  2023cites this paper
• Recent advances and perspectives on natural latex serum and its fractions for biomedical applications.

  2023cites this paper
• Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

  2023cites this paper
• VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway

  2023cites this paper
• N-glycosylation acts as a switch for FGFR1 trafficking between the plasma membrane and nuclear envelope

  2023cites this paper
• Angiogénesis y activación de la coagulación en linfoma no Hodgkin

  2023cites this paper
• FGF-trapping hampers cancer stem-like cells in uveal melanoma

  2023cites this paper
• Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach.

  2023cites this paper
• A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis

  2023cites this paper
• Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement

  2023cites this paper
• Elucidating Fibroblast Growth Factor–Induced Kinome Dynamics Using Targeted Mass Spectrometry and Dynamic Modeling

  2023cites this paper
• Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies

  2023cites this paper
• Targeted Therapies for Perihilar Cholangiocarcinoma

  2022cites this paper
• Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology

  2022cites this paper
• Blockade of FGF2/FGFR2 partially overcomes bone marrow mesenchymal stromal cells mediated progression of T-cell acute lymphoblastic leukaemia

  2022cites this paper
• Artificial Extracellular Matrix Composed of Heparin-Mimicking Polymers for Efficient Anticoagulation and Promotion of Endothelial Cell Proliferation.

  2022cites this paper
• Repulsion and attraction in searching: A hybrid algorithm based on gravitational kernel and vital few for cancer driver gene prediction

  2022cites this paper
• Inhibition of FGFR Signaling by Targeting FGF/FGFR Extracellular Interactions: Towards the Comprehension of the Molecular Mechanism through NMR Approaches

  2022cites this paper
• Molecular diagnostics and biomarkers in cholangiocarcinoma.

  2022cites this paper
• Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer

  2022cites this paper
• Circular RNA circLRCH3 promotes oxaliplatin resistance in gastric cancer through the modulation of the miR-383-5p/FGF7 axis.

  2022cites this paper
• Clinical treatment of cholangiocarcinoma: an updated comprehensive review.

  2022cites this paper
• Sulfated Galactofucans: An Outstanding Class of Fucoidans with Promising Bioactivities

  2022cites this paper
• The current state of molecular profiling in gastrointestinal malignancies

  2022cites this paper
• MicroRNA-106b-5p (miR-106b-5p) suppresses the proliferation and metastasis of cervical cancer cells via down-regulating fibroblast growth factor 4 (FGF4) expression

  2022cites this paper
• FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma

  2022cites this paper
• Changing Landscape of Systemic Therapy in Biliary Tract Cancer

  2022cites this paper
• Antitumor effect of memantine is related to the formation of the splicing isoform of GLG1, a decoy FGF‑binding protein.

  2022cites this paper
• Hypoxia promotes thyroid cancer progression through HIF1α/FGF11 feedback loop.

  2022cites this paper
• Nanodiamonds as traps for fibroblast growth factors: Parameters influencing the interaction

  2022cites this paper
• Interleukin-17 receptor D is a favorable biomarker of glioblastoma.

  2022cites this paper
• Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments

  2022cites this paper
• Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives

  2022cites this paper
• Role of Fibroblast Growth Factors in the Crosstalk of Hepatic Stellate Cells and Uveal Melanoma Cells in the Liver Metastatic Niche

  2022cites this paper
• Effects of some cosmetic dyes and pigments on the proliferation of human foreskin fibroblasts and cellular oxidative stress; potential cytotoxicity of chlorophyllin and indigo carmine on fibroblasts

  2022cites this paper
• New developments in the biology of fibroblast growth factors.

  2022cites this paper
• Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer

  2022cites this paper
• Emerging self-assembling peptide nanomaterial for anti-cancer therapy

  2021cites this paper
• Protopine/Gemcitabine Combination Induces Cytotoxic or Cytoprotective Effects in Cell Type-Specific and Dose-Dependent Manner on Human Cancer and Normal Cells

  2021cites this paper
• TGF-β1-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor

  2021cites this paper
• Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.

  2021cites this paper
• Fermentation, Purification, and Tumor Inhibition of a Disulfide-Stabilized Diabody Against Fibroblast Growth Factor-2

  2021cites this paper
• Role of fibroblast growth factor signalling in hepatic fibrosis

  2021cites this paper
• Effects of metformin on lipopolysaccharide induced inflammation by activating fibroblast growth factor 21

  2021cites this paper
• Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases

  2021cites this paper
• Targeting FGFR inhibition in cholangiocarcinoma.

  2021cites this paper
• FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue

  2021cites this paper
• A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers

  2021cites this paper
• Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells

  2021cites this paper
• Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response

  2021cites this paper
• 2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology

  2021cites this paper
• Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma.

  2021cites this paper
• Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer

  2021influential citation
• Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors

  2021cites this paper
• Tumor angiogenesis: Current challenges and therapeutic opportunities.

  2021cites this paper
• Role of FGF15 in Hepatic Surgery in the Presence of Tumorigenesis: Dr. Jekyll or Mr. Hyde?

  2021cites this paper
• Efficacy and Selectivity of FGF2-Saporin Cytosolically Delivered by PCI in Cells Overexpressing FGFR1

  2021cites this paper
• Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas

  2021cites this paper
• Spatiotemporal sensitivity of mesoderm specification to FGFR signalling in the Drosophila embryo

  2021cites this paper
• DARK AND BRIGHT SIDE OF TARGETING THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN THE LIVER.

  2021cites this paper
• The Role of Neutrophil Extracellular Traps in Cancer

  2021influential citation
• Molecular-driven treatment for biliary tract cancer: the promising turning point

  2021cites this paper
• Natural Polymeric-Based Composites for Delivery of Growth Factors

  2021cites this paper
• Comprehending fibroblast growth factor receptor like 1: Oncogene or tumor suppressor?

  2021cites this paper
• FGF10/FGF17 as prognostic and drug response markers in acute myeloid leukemia.

  2021cites this paper